ArticleActa pharmaceutica Sinica. B2019
Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters.
Article in Acta pharmaceutica Sinica. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 196 citations in OpenAlex.
- Circulating Profiles of the Bile Acid Metabolomics in Patients With Polycystic Ovary Syndrome Treated With Metformin or Canagliflozin.Pharmacotherapy · 2026Trial
- Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2022Trial
- Curcumin ameliorates fatty liver hemorrhagic syndrome in broiler breeders by regulating lipid metabolism via the gut-liver axis.Poultry science · 2026Article
- The Dual Role of the Gut Microbiota in Cancer Chemoresistance.MicrobiologyOpen · 2026Review
- Article
- Liuweidihuang Pill Attenuates Early Bleomycin-Induced Pulmonary Fibrosis in Mice and Is Associated with Gut Microbiome.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Si-Wu-Tang Targets Microbiota Homeostasis and Intestinal Mucosal Barriers to Provide Protection Against MASLD by FavoringPharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Sevelamer inhibits the formation of cholesterol gallstones by modulating bile acid metabolism.Frontiers in pharmacology · 2026Article
- Multiomics analysis elucidated the role of inflammatory response and bile acid metabolism disturbance in electric shock-induced liver injury in mice.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026Article
- The dysbiosis of gut microbiota in major depressive disorder and comorbidity with overweight/obesity: unraveling biomarkers and metabolic pathways from a microbial perspective.BMC psychiatry · 2025Article
- Enhancing milk quality and modulating plasma lipid metabolism of lactating dairy goats: The impact of bile acid supplementation.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2025Article
- Novel Approaches in Glucose and Lipid Metabolism Disorder Therapy: Targeting the Gut Microbiota-Bile Acid Axis.Biology · 2025Review
- Longitudinal multi-omics analysis of the gut-liver axis: Unraveling the molecular mechanisms of metabolic homeostasis regulation by Pd@Pt nanozymes.Materials today. Bio · 2025Article
- Non-starch polysaccharides and health: gut-target organ axis influencing obesity.Food science and biotechnology · 2025Review
- Ablation of Gut Microbiota Alleviates DON-Induced Neurobehavioral Abnormalities and Brain Damage in Mice.Toxins · 2025Article
- Gut microbiota-mediated bile acid transformations regulate the transport of aflatoxin B1 from the intestine to the liver in piglets.Journal of animal science and biotechnology · 2025Article
- Vitisin A Outperforms Cyanidin-3-O-Glucoside in Triglyceride Reduction by Modulating Hepatic Lipogenesis and Fatty Acid β-Oxidation.International journal of molecular sciences · 2025Article
- GLP-1RAs attenuated obesity and reversed leptin resistance partlyActa pharmaceutica Sinica. B · 2025Article
- Study on the molecular mechanisms of rifaximin in the treatment of non‑alcoholic steatohepatitis based on theMolecular medicine reports · 2025Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since metabolic process differs between humans and mice, studies were performed in hamsters, which are generally considered to be a more appropriate animal model for studies of obesity-related metabolic disorders. The modulation of gut microbiota, bile acids and the farnesoid X receptor (FXR) axis is correlated with obesity-induced insulin resistance and hepatic steatosis in mice. However, the interactions among the gut microbiota, bile acids and FXR in metabolic disorders remained largely unexplored in hamsters. In the current study, hamsters fed a 60% high-fat diet (HFD) were administered vehicle or an antibiotic cocktail by gavage twice a week for four weeks. Antibiotic treatment alleviated HFD-induced glucose intolerance, hepatic steatosis and inflammation accompanied with decreased hepatic lipogenesis and elevated thermogenesis in subcutaneous white adipose tissue (sWAT). In the livers of antibiotic-treated hamsters, cytochrome P450 family 7 subfamily B member 1 (CYP7B1) in the alternative bile acid synthesis pathway was upregulated, contributing to a more hydrophilic bile acid profile with increased tauro-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.